A Study of CaBozantinib in Patients With Advanced or Unresectable Renal

See also
Status	Clinical Trial	Phase
Completed	`NCT00930033` - Clinical Trial to Assess the Importance of Nephrectomy	Phase 3
Recruiting	`NCT05863351` - Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study	Phase 3
Not yet recruiting	`NCT06284564` - A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)	Phase 2
Completed	`NCT00414765` - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma	Phase 4
Active, not recruiting	`NCT03149822` - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma	Phase 1/Phase 2
Recruiting	`NCT03647878` - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed	`NCT01517243` - Phase II Study of Alternating Sunitinib and Temsirolimus	Phase 2
Withdrawn	`NCT03927248` - PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer	Phase 1/Phase 2
Terminated	`NCT02122003` - Second Line Sorafenib After Pazopanib in Patients With RCC	Phase 2
Completed	`NCT01182142` - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients	Phase 2
Completed	`NCT00630409` - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Completed	`NCT04076787` - Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Active, not recruiting	`NCT04467021` - Cancer and Blood Pressure Management, CARISMA Study	N/A
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT02282579` - Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
Terminated	`NCT02071641` - Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma	Phase 2
Completed	`NCT01731158` - Sequential Therapy in Metastatic Renal Cell Carinoma	Phase 2
Terminated	`NCT01342627` - Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT01274273` - Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer	Phase 2

NCT number	NCT03463681
Study type	Interventional
Source	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact
Status	Completed
Phase	Phase 2
Start date	June 11, 2018
Completion date	April 8, 2021

A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma — BREAKPOINT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms